Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study. J of Skin [Internet]. 2024 Nov. 18 [cited 2026 Apr. 18];8(6):s451. Available from: https://skin.dermsquared.com/skin/article/view/3041